LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

Search

Design Therapeutics Inc

Fermé

5.79 -4.77

Résumé

Variation du prix de l'action

24h

Actuel

Min

5.77

Max

6.27

Chiffres clés

By Trading Economics

Revenu

-1.4M

-19M

Marge bénéficiaire

-2,321.599

Employés

57

EBITDA

-1.3M

-22M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

-22.48% downside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

90M

315M

Ouverture précédente

10.56

Clôture précédente

5.79

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Design Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 sept. 2025, 23:59 UTC

Acquisitions, Fusions, Rachats

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 sept. 2025, 22:02 UTC

Principaux Mouvements du Marché

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 sept. 2025, 17:01 UTC

Principaux Mouvements du Marché

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 sept. 2025, 17:01 UTC

Principaux Mouvements du Marché

Tron Shares Rise After New Investment From Bravemorning

8 sept. 2025, 16:14 UTC

Principaux Mouvements du Marché

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 sept. 2025, 16:13 UTC

Principaux Mouvements du Marché

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 sept. 2025, 23:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 sept. 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

8 sept. 2025, 23:12 UTC

Market Talk

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 sept. 2025, 22:56 UTC

Market Talk

Worst May Be Over for New Zealand Retailers -- Market Talk

8 sept. 2025, 22:23 UTC

Market Talk

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 sept. 2025, 21:51 UTC

Market Talk

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 sept. 2025, 21:47 UTC

Principaux Mouvements du Marché

Microsoft Signs $17.4B AI Deal With Nebius

8 sept. 2025, 21:33 UTC

Acquisitions, Fusions, Rachats

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 sept. 2025, 21:20 UTC

Acquisitions, Fusions, Rachats

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 sept. 2025, 21:19 UTC

Acquisitions, Fusions, Rachats

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 sept. 2025, 21:18 UTC

Acquisitions, Fusions, Rachats

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 sept. 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

8 sept. 2025, 19:33 UTC

Market Talk

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 sept. 2025, 19:22 UTC

Market Talk

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 sept. 2025, 19:02 UTC

Market Talk

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 sept. 2025, 18:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 sept. 2025, 18:24 UTC

Market Talk

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 sept. 2025, 17:29 UTC

Market Talk

Mexican Inflation Seen Little Changed in August -- Market Talk

8 sept. 2025, 16:59 UTC

Market Talk
Acquisitions, Fusions, Rachats

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 sept. 2025, 16:36 UTC

Market Talk

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 sept. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 sept. 2025, 16:16 UTC

Résultats

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 sept. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 sept. 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

Comparaison

Variation de prix

Design Therapeutics Inc prévision

Objectif de Prix

By TipRanks

-22.48% baisse

Prévisions sur 12 Mois

Moyen 5 USD  -22.48%

Haut 5 USD

Bas 5 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

2 ratings

0

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

3.26 / 3.63Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
help-icon Live chat